We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bilanz Biontech 2023: Onkologie und Impfstoffe.
- Authors
Bulmahn, Maren
- Abstract
The Mainz-based company Biontech experienced a decline in revenue in 2023 but is working on expanding its portfolio beyond Covid-19 vaccines. One focus is on the development of treatments for tumor diseases. Biontech's revenue in 2023 amounted to 3.82 billion euros, which corresponds to a decrease of 22 percent compared to the previous year. This decline is mainly due to reduced production and sales of Covid-19 vaccines. Biontech also invested in clinical trials and new products, particularly in the development of oncological preparations and medications against infectious diseases. The company aims to obtain approvals in ten indications in oncology by 2030 and expects revenue of 2.5 to 3.1 billion euros for the year 2024.
- Subjects
MAINZ (Germany : Landkreis); BIONTECH SE; COVID-19 vaccines; THERAPEUTICS; TUMOR treatment; NEW trials; COMMUNICABLE diseases
- Publication
Nachrichten aus der Chemie, 2024, Vol 72, Issue 5, p44
- ISSN
1439-9598
- Publication type
Article
- DOI
10.1002/nadc.20244141019